Diabetic Nephropathy

Definition and Pathophysiology

• Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in the United States and Europe, accounting for about 40% of new ESRD cases 1
• The condition develops due to chronic hyperglycemia causing damage to kidney blood vessels, particularly affecting the glomeruli 2
• Diabetic nephropathy is characterized by a progressive increase in urinary albumin excretion and declining glomerular filtration rate (GFR) 2

Natural History and Progression

• The earliest clinical evidence is microalbuminuria, defined as urinary albumin excretion of 30-299 mg/24h or 20-199 μg/min 1, 3
• Without intervention, 80% of type 1 diabetes patients with sustained microalbuminuria progress to overt nephropathy over 10-15 years 1
• Hypertension typically develops alongside increasing albuminuria 2
• Characterized by clinical albuminuria (macroalbuminuria) ≥300 mg/24h or ≥200 μg/min 1, 3
• Once overt nephropathy occurs, GFR gradually declines at a variable rate (2-20 ml/min/year) 2
• Without specific interventions, ESRD develops in 50% of type 1 diabetic patients with overt nephropathy within 10 years and in 75% by 20 years 1

Differences Between Type 1 and Type 2 Diabetes

• In type 1 diabetes, nephropathy typically develops after 10-15 years of diabetes duration 2
• In type 2 diabetes, microalbuminuria and overt nephropathy may be present shortly after diagnosis because diabetes often exists for years before diagnosis 2
• Without intervention, 20-40% of type 2 diabetes patients with microalbuminuria progress to overt nephropathy 2
• By 20 years after onset of overt nephropathy, only about 20% of type 2 diabetes patients will have progressed to ESRD 2

Risk Factors

• Racial/ethnic variations exist with higher risks in Native Americans, Hispanics (especially Mexican-Americans), and African-Americans compared to non-Hispanic whites 1
• Male sex and prolonged duration of diabetes increase risk 4
• Poor glycemic control and hypertension accelerate progression 4
• Early decrease in GFR, elevated uric acid levels, and presence of albuminuria are predictors of progression 4

Clinical Implications

• Albuminuria is not only a marker of kidney disease but also indicates greatly increased cardiovascular morbidity and mortality 2

Diagnosis

• Diagnosis requires confirmation with 2 of 3 specimens collected within a 3-6 month period 3
• Standard hospital laboratory assays for urinary protein are often not sensitive enough to detect microalbuminuria; specific assays are needed 3
• Assessment should include both urinary albumin excretion and estimated glomerular filtration rate (eGFR) 3

Treatment Approach

• Early intervention is crucial as treatments have their greatest impact when instituted early in the course of nephropathy 1
• Aggressive control of blood pressure and blood glucose are cornerstones of treatment 3

Prevention Strategies

• Regular monitoring of blood glucose and kidney function is essential 3
• Comprehensive cardiovascular risk factor management (including lipid control, smoking cessation, and exercise) is recommended upon finding microalbuminuria 1

Special Considerations

• About 40% of type 2 diabetes patients with microalbuminuria show typical diabetic nephropathy changes on biopsy, while approximately 30% have normal or near-normal findings despite having albuminuria 3
• Consider non-diabetic kidney disease in patients with atypical presentations 3

Diabetic Nephropathy Progression and Mortality

Stage 2: Macroalbuminuria (Overt Nephropathy)

• This stage is often associated with neuropathy and diabetic retinopathy, revealing concurrent microvascular complications 5

Stage 3: Progressive Renal Decline

• The progression to end-stage renal failure has slowed over recent years: 4-15% in 20 years and 16% in 30 years 5

Stage 4: End-Stage Renal Disease

• Diabetic nephropathy is the most frequent cause of ESRD, affecting 45% of individuals with renal failure in the USA 5
• Twenty-four to 50% of patients receiving dialysis are diabetics with ESRD 5
• Mortality rate of diabetic patients between 18-44 years of age on dialysis reaches 30% in 5 years compared to 11% in dialyzed non-diabetic patients 5

Key Predictors of Rapid Progression

• Raised HbA1c and raised blood pressure are the most modifiable risk factors 5
• Presence of albuminuria and early decrease in GFR predict faster progression 5
• Elevated uric acid levels accelerate decline 5
• Male sex, South Asian or Afro-Caribbean ethnicity, and prolonged diabetes duration increase risk 5

Mortality Impact

• Diabetic nephropathy increases mortality risk 40-100 times higher than in non-diabetics, regardless of diabetes type 5

Diabetic Nephropathy Management and Prognosis

Screening and Diagnosis

• The American Diabetes Association recommends beginning annual microalbuminuria screening after 5 years of disease duration for type 1 diabetes, and immediately at diagnosis for type 2 diabetes, with confirmation requiring 2 of 3 positive specimens within 3-6 months 6
• The preferred screening method is the spot urine albumin-to-creatinine ratio 6

Staging and Prognosis

• Diabetic nephropathy is defined by urinary albumin excretion between 15-300 μg/min (or 30-299 mg/24h) at Stage 3, with 80% of type 1 diabetes patients progressing to overt nephropathy over 10-15 years, and 20-40% of type 2 diabetes patients progressing 6
• The 10-year all-cause mortality increases from 11.5% in diabetes without kidney disease to 31% with diabetic kidney disease, with cardiovascular death being more likely than progression to kidney failure 7

Treatment and Management

• The American College of Cardiology recommends initiating ACE inhibitor or ARB therapy regardless of blood pressure status at Stage 3, with a target blood pressure ≤130/85 mmHg, and titrating ACE inhibitor/ARB to maximum approved dose for greater antiproteinuric effect 6
• The Mayo Clinic recommends adding SGLT2 inhibitors as first-line therapy for renoprotection, and considering GLP-1 receptor agonists for cardiovascular and kidney protection at Stage 4 7

Prognostic Indicators

• The rate of albumin excretion increase (typically 10-20% per year in Stage 3) predicts progression, with early decrease in GFR and presence of albuminuria being the strongest predictors of rapid progression 6
• Both albuminuria level and reduced eGFR independently and additively increase cardiovascular and all-cause mortality 7